Company profile
Home - C4XD
Combining cutting-edge Drug Discovery technologies and expertise to efficiently deliver world-leading medicines.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
CS01 | Transaction MzUyOTc5Njk5OGFkaXF6a2N4
Published 02 Jul 2026 10:23
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
AP01 | Transaction MzQ1MDcwMjg4N2FkaXF6a2N4 | Paper/PDF filed
Published 30 Jun 2026 22:59
Company registered at Companies House
C4X Discovery (Previously trading as Conformetrix) develops a drug discovery system, that aims to screen small molecule pharmaceutical candidates for the treatment of inflammation, cancers and neurological conditions.
C4X Discovery operates a hybrid business model of a wholly owned pipeline of discovery programmes plus partnerships with global and international companies, from top 10 pharma through to biotech. The Company is partnered with the Structural Genomic Consortium to assist with the identification and validation of new drug targets and has several active research collaborations with academic institutions. By 2012 Conformetrix disclosed its first collaborative deal with AstraZeneca. Mike Snowden, Vice President and Head of Discovery Sciences, AstraZeneca, said at the time: "We are excited to be working with Conformetrix. We believe their technology will provide a powerful addition to our hit identification and lead optimization approaches, supporting our strategic objectives to improve the quality and choice of candidate compounds for our early pipeline." In addition to an undisclosed upfront payment, Conformetrix received research funding and was eligible for milestones as certain targets are met. At the end of 2012 Conformetrix announced that it had used its technology to generate a series of potent orexin (OX-1) antagonists, with plans to progress to drug leads. Orexin is a neurotransmitter believed to play a role in a broad range of behavioral conditions, from sleep disorders to addiction. In 2013 Conformetrix was rebranded to C4XDiscovery Ltd and in the same year announced how its proprietary NMR-based technology could be used to solve the dynamic solution-structure of a small molecule antagonist of the Class B GPCR corticotropin-releasing factor receptor (CRF-1R) in just seven days. In 2014 C4XDiscovery announced new collaboration deals with Takeda Pharmaceuticals and Evotec AG. Furthermore, the company published further positive data and announced a patent filing for its selective OX-1 inhibitor programme for stress-related addictive disorders. On the basis of these positive corporate results, and to maintain investment in C4XDiscovery's programmes, the company successfully floated on the London Stock Exchange in an Oct 2014 IPO, valuing the company at £31m. Further announcements since then: 2014. Renewed collaboration with Evotec AG, including co-development of selective OX-1 inhibitors. 2015. Selection of drug candidate from OX-1 programme to enter pre-clinical development. New collaboration with Structural Genomics Consortium at Oxford University. Small molecule leads against IL-17 for inflammation and autoimmune diseases. Breakthrough compounds for diabetes and inflammation. 2016. Appointment of Clive Dix as Chief Executive Officer. Acquisition of Adorial Limited (a genetic analysis company). Acquisition of MolPlex Limited (drug-discovery technologies). Further £5m fundraise. New strategic multi-target, risk-sharing alliance with Evotec AG.
1 May 2019 to 30 Jun 2022
To transfer, and embed into drug discovery, cutting edge biomolecular NMR techniques for the characterisation of dynamics of protein: ligand complexes in solution. Synergies will be identified and developed with the proprietary ligand NMR technology.
1 Nov 2018 to 30 Sep 2019
"The objective for this project is to deliver an oral, small molecule anti-inflammatory agent for the treatment of mild-severe, inflammatory bowel disease (IBD). IBD is a collection of idiopathic diseases caused by a dysregulated immune response to host intestinal microflora. The most common sub-types are ulcerative colitis (a continuous band of inflammat...
1 Jan 2017 to 31 Dec 2017
Type-2 diabetes (T2D) affects over 420 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently reported to be an exciting new target for the treatment of T2D with several advantages. Firstly, its activation results in insulin secretion but only in the presence of high blood sugar levels, a...
1 Apr 2015 to 31 Dec 2015
Type-2 diabetes (T2D) affects over 340 million people worldwide, creating an enormous healthcare and socio-economic burden. The GPR142 receptor has been recently suggested as a potential new target for treating T2D with a key advantage: its activation results in insulin secretion as desired but, unlike other targets, it does this only in the presence of h...
1 Jul 2014 to 30 Sep 2015
Type-2 diabetes has assumed almost epidemic proportions, resulting in a significant financial burden to healthcare systems in developed countries. GLP-1R agonism represents one of the mainstays of therapy for type-2 diabetes, but existing GLP-1 mimetics necessitate injection and have been associated with severe side effects. Through the use of its proprie...
